Investment trend Xinxu completes Series C financing to promote the development and commercialization of diagnostic and therapeutic drugs for neurodegenerative diseases

Today, APRINOIA Therapeutics, a company in the BioBAY Park, announced that it has completed a Series C financing totaling US$40 million
.

The funds raised by Xinxu this time are mainly used to promote the domestic phase III clinical trials and commercialization of the Alzheimer’s disease tau protein positron emission tomography (PET) tracer, and to continue the development of neurodegenerative diseases Drugs
.

In addition, the company will continue to expand its drug discovery and development platform and pipeline, and work with domestic and foreign partners to build a leading and international-level brain PET clinical imaging alliance
.

 In addition to the continued support of the original shareholders including KTB Network, IMM Private Equity, and Tai'an Biotech, this round of financing also ushered in Yantai Dongcheng Pharmaceutical Group and Suzhou Yuanfeng Capital Management Co.
, Ltd.
, a subsidiary of Suzhou Industrial Park.
The participation of pharmaceutical companies and investment institutions deepens Xinxu's presence in China
.

Dongcheng Pharmaceutical, led by the C round of financing, has businesses covering biochemical raw materials, chemical medicines, Chinese patent medicines, and nuclear medicines
.

In the field of nuclear medicine, it has the advantages of the whole industry chain layout and transportation from diagnostic nuclear medicine to therapeutic nuclear medicine, which can cover the accelerated growth of PET-CT and other inspection equipment nationwide and the demand for disease diagnosis and treatment in the future
.

 According to the results of the National Nuclear Medicine Census in 2020, although the number of positron imaging equipment in the country has increased by 39% compared with 2017 [1], the number of PET/CT per million population in China is 2.
14, which is still far lower than that of the United States.
4.
39 and 4.
18 in South Korea [2]
.

Therefore, although the number of nuclear medicine equipment in China has increased significantly, there is still a lot of room for improvement compared with other countries
.

At the same time, there is a lack of new nuclear medicine drugs in China.
This is also the original intention of Xinxu to work with partners to accelerate the popularization of nuclear medicine in China and actively treat neurodegenerative diseases with accurate diagnosis
.

 Luo Zhigang, general manager of Dongcheng Pharmaceuticals, said: “The layout of Dongcheng Pharmaceuticals in the field of nuclear medicine and Xinxu’s diagnostic drugs for neurodegenerative diseases are complementary.
Dongcheng is leading the investment in Xinxu to promote the sharing of resources between the two parties.
Accelerate the development of Xinxu's diagnostic and therapeutic drugs for neurodegenerative diseases, and meet the momentum of global pharmaceutical companies aiming at the development of drugs for the diagnosis and treatment of Alzheimer's disease
.

Dongcheng hopes that the cooperation with Xinxu can further create domestic nuclear medicine imaging diagnostic imaging The platform sets a benchmark for jointly building a leading international standardized diagnosis and treatment process
.

” Sheng Gang, general manager of Suzhou Yuanfeng Capital, said: “Alzheimer’s disease is a very serious senile neurodegenerative disease that seriously affects patients and their families.
There are nearly 10 million patients in China alone, and there is no effective treatment in the world
.

Therefore, early diagnosis and intervention are effective means to delay the onset of the disease
.

However, the current clinical practice is mainly carried out by questionnaire surveys, subject to subjectivity The impact of sex is greater
.

Xinxu’s target tau protein 18F-APN-1607 tracer can effectively distinguish the stage of onset of patients, and can be used for early diagnosis to further solve the pain points faced by the current clinical practice
.

As a Suzhou Industrial Park Industrial Investment Fund, It is a great honor to work with new and existing shareholders to help the company's development in the Suzhou Industrial Park, and to provide more reliable diagnosis and treatment options for Alzheimer's patients around the world
.

The impact of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease on patients and society is currently one of the most important public health issues in the world, and it is heavy on patients, their families, and the national medical system.
social burden
.

one study indicates that in 2019 China Alzheimer's disease and other dementias number of patients to 13,143,950 cases, accounting for 25.
5% of the global amount [3]
.

in addition, in terms of Parkinson's disease, there are about 310 10,000 Parkinson’s disease patients, and with the aging problem getting worse, it is estimated that by 2030, the number of Parkinson’s disease patients in China will surge to about 5 million [4]
.

From the perspective of social cost, the study pointed out that in 2015 An Alzheimer’s disease patient spends nearly RMB 130,000 per year, and the social cost for a year is as high as 1.
085 trillion yuan
.

This cost will increase to approximately 3.
3 trillion yuan in 2030, and nearly 12 trillion yuan in 2050 [ 5]
.

How to improve the public’s awareness of early diagnosis in order to achieve better disease control and management, on the one hand, reduce the rate of disease growth, and on the other hand, reduce the burden of all aspects, it is urgent
.
For
 neurodegenerative diseases, the Xinxu R&D team is constructed The unique compound and antibody screening technology platform is designed to design drugs with diagnostic or therapeutic functions for small molecule compounds, protein degradation agents and antibodies that can specifically target diseased proteins
.

Among them, Xinxu's antibody therapy drug APN-mAb005 is in the preclinical stage The experiment has also made concrete progress
.

APN-mAb005 can accurately identify pathological tau protein accumulated in nerve synapses, and does not interact with normal tau protein to prevent pathological tau protein from being transmitted between nerve cells
.

Xinxu plans to promote this treatment in China and overseas next year Clinical trials of drugs
.

Zhang Mingkui, Chairman and CEO of Xinxu Group, pointed out: "The completion of the C round of financing is the beginning of a new phase of Xinxu's leap forward, and it is expected to accelerate the realization of Xinxu Precision Medical's vision of neurodegenerative diseases
.

Thanks to the new and existing shareholders for helping us to gain a foothold in Asia , Going international, benefiting the patients and their families suffering from neurodegenerative diseases
.

"End Reference source: [1]] 2020 National Nuclear Medicine Survey Results Briefing, Chinese Journal of Nuclear Medicine and Molecular Imaging, 2020, 40( 12): 747-749.
DOI: 10.
3760/cma.
j.
cn321828-20201109-00403 [2] National Nuclear Medicine Status and Development Trend Research Analysis, International Journal of Radiation Medicine and Nuclear Medicine, Vol.
44 No.
2, February 2020 [3] "China Alzheimer's Disease Report 2021", Diagnostic Theory and Practice, Volume 20, Issue 4, 2021
.

[4] "Initiation of the survey on the current quality of life of patients with Parkinson's disease in China" https://3w.
huanqiu.
com/a/c36dc8/42mnnc7vDbj?p=1&agt=46[5]The cost of Alzheimer's disease in China and re-estimation of costs worldwide, J.
Jia et al.
/ Alzheimer's & Dementia 14(2018) 483-491 Selected onlookers in the past The Lancet: Five types of cancer are discovered, early screening and early diagnosis are not empty words! The stock price of the Big Three is cut in half.
Is the trillion-level Internet medical track still "sweet"? Rewen vaccination can prolong life! Nature Sub-Journal: Anti-aging Vaccines Selective Elimination of Senescent Cells to Prolong Lifespan The Counterattack of Exosomes From "Cell Garbage" to "Rookie Seed" How does the original article reshape the tumor microenvironment and strengthen the efficacy of anti-PD-1? Blimp1 expression in Treg cells is the key to medicine immunotherapy| biosimilars| vaccines| drug resistance| drug targets| healthy life| pharmaceutical company news| drug inventory| pharmaceutical technology| basic research on side effects of drugs/ translational medicine leukemia| lung cancer| gastric cancer | Colorectal Cancer | Liver Cancer | Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegenerative Diseases | Intestinal Microbial Medical Devices / Biotechnology In Vitro Diagnosis | Medical Devices | Bio-Nano | 3D Printing | Gene Testing | Single Cell Sequencing | Genes Editor| Assisted Reproduction| Artificial Intelligence| Precision Medicine Policy Anti-cancer Drugs| 4+7 Quantity Procurement| Consumables| Filing System| Registrant System| Healthy China| New Edition Basic Medicine Catalog| AI Medical Devices| Telemedicine| Different Rights of Same Share Market/Capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | Growth Enterprise Market | R & D Investment | Acquisitions |